---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006455"
form_type: "8-K"
ticker: null
cik: "0001783032"
company_name: "Elevation Oncology, Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:46:24.143696+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Elevation Oncology Q1 net loss $10.7M; cash $104.1M; EO-3021 trial ongoing

## Summary
- Net loss of $10.7M improved from $17.1M in Q1 2023; R&D expenses $6.0M, G&A $3.9M.
- Cash and marketable securities $104.1M at March 31, 2024; raised $44.2M YTD via ATM, extending runway into 2026.
- Enrollment ongoing in Phase 1 trial of EO-3021 (Claudin 18.2 ADC); initial safety/efficacy data expected by mid-3Q 2024.
- Presented preclinical proof-of-concept for HER3-ADC program at AACR; development candidate nomination planned for 2H 2024.
- Plans to share details of EO-3021 combination study in 1H 2024; additional data expected in 1H 2025.

## SEC filing metadata
- accession: 0001558370-24-006455
- form_type: 8-K
- cik: 0001783032
- company_name: Elevation Oncology, Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/0001558370-24-006455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/elev-20240502x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006455
- JSON: https://secwatch.observer/filing/0001558370-24-006455.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006455.txt

## Key facts
- Earnings Releases
  Elevation Oncology, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 2, 2024, Elevation Oncology, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783032/000155837024006455/0001558370-24-006455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.